Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

被引：264

作者：

Vanderstichele, Hugo ^{[1
]}

Bibl, Mirko ^{[2
]}

Engelborghs, Sebastiaan ^{[3
,4
,5
]}

Le Bastard, Nathalie ^{[3
,4
]}

Lewczuk, Piotr ^{[6
]}

Molinuevo, Jose Luis ^{[7
]}

Parnetti, Lucilla ^{[8
]}

Perret-Liaudet, Armand ^{[9
,10
]}

Shaw, Leslie M. ^{[11
]}

Teunissen, Charlotte ^{[12
]}

Wouters, Dirk ^{[1
]}

Blennow, Kaj ^{[13
]}

机构：

[1] Innogenetics NV, Ghent, Belgium

[2] Univ Duisburg Essen, Dept Psychiat Psychotherapy & Addict Med, Kliniken Essen Mitte, Essen, Germany

[3] Hosp Network Antwerp ZNA, Dept Neurol, Antwerp, Belgium

[4] Hosp Network Antwerp ZNA, Memory Clin, Antwerp, Belgium

[5] Univ Antwerp, Inst Born Bunge, Reference Ctr Biol Markers Dementia BIODEM, B-2020 Antwerp, Belgium

[6] Univ Klinikum Erlangen, Dept Psychiat & Psychotherapy, Erlangen, Germany

[7] Hosp Clin & Univ, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona, Spain

[8] Univ Perugia, Neurol Sect, Ctr Memory Disturbances, I-06100 Perugia, Italy

[9] Hop Lyon, CMRR, Neurobiol Lab, GHE, Lyon, France

[10] Univ Lyon 1, Ctr Rech Neurosci Lyon Equipe BioRaN, CNRS UMR5292, INSERM U1028, F-69365 Lyon, France

[11] Univ Penn, Dept Pathol & Lab Med, Perelman Med Ctr, Philadelphia, PA 19104 USA

[12] Vrije Univ Amsterdam Med Ctr, Neurol Lab Clin Chem, Amsterdam, Netherlands

[13] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Clin Neurochem Lab,Inst Neurosci & Phys, Molndal, Sweden

来源：

ALZHEIMERS & DEMENTIA | 2012年 / 8卷 / 01期

关键词：

Alzheimer's disease; Amyloid-beta; Biomarkers; Cerebrospinal fluid; Consensus; Standardization; Tau; POSTLUMBAR PUNCTURE HEADACHE; POSTERIOR CORTICAL ATROPHY; AMYLOID-BETA PEPTIDES; ASSOCIATION WORKGROUPS; NATIONAL INSTITUTE; CSF BIOMARKERS; DEMENTIA; TAU; RECOMMENDATIONS; GUIDELINES;

D O I：

10.1016/j.jalz.2011.07.004

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Numerous studies show that the cerebrospinal fluid biomarkers total tau (T-tau), tau phosphorylated at threonine 181 (P-tau(181P)), and amyloid-beta (1-42) (A beta(1-42)) have high diagnostic accuracy for Alzheimer's disease. Variability in concentrations for A beta(1-42), T-tau, and P-tau(181P) drives the need for standardization. Methods: Key issues were identified and discussed before the first meeting of the members of the Alzheimer's Biomarkers Standardization Initiative (ABSI). Subsequent ABSI consensus meetings focused on preanalytical issues. Results: Consensus was reached on preanalytical issues such as the effects of fasting, different tube types, centrifugation, time and temperature before storage, storage temperature, repeated freeze/thaw cycles, and length of storage on concentrations of A beta(1-47), T-tau, and P-tau(181P) in cerebrospinal fluid. Conclusions: The consensus reached on preanalytical issues and the recommendations put forward during the ABSI consensus meetings are presented in this paper. (C) 2012 The Alzheimer's Association. All rights reserved.

引用

页码：65 / 73

页数：9

共 59 条

[1] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J].